Has Salah El Hafi received payments from drug or device companies?

Yes. Drug and device makers reported $5,100 in general payments to Salah El Hafi across 108 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Salah El Hafi did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Salah El Hafi come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Salah El Hafi

Interventional Cardiology · Houston, TXNPI 1396969622

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (52.0%), food and beverage and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 69.5% of it on its own, with 17 other manufacturers making up the rest. That places this record below the midpoint for interventional cardiology clinicians in TX, where the typical reported total is $9,094.

$5,100in general payments, 2019–2025

Across 108 payments — averaging $47.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$4K
Astellas Pharma US Inc$268
Johnson & Johnson$185
Amgen$167
AstraZeneca$149
Actelion Pharmaceuticals US, Inc.$141
plus $645 from 12 others

$4,374in research payments, 2019–2025

Across 2 payments — averaging $2187.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AstraZeneca$3K
Novartis$1K

What the payments were for

Travel & lodging$2,65352%
Food & beverage$2,25244%
Education$1954%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic	25	$3,545
Astellas Pharma US Inc	7	$268
Johnson & Johnson	15	$185
Amgen	9	$167
AstraZeneca	12	$149
Actelion Pharmaceuticals US, Inc.	2	$141
Boehringer Ingelheim	7	$130
Sanofi-aventis U.S. LLC	5	$101
Regeneron Healthcare Solutions, Inc.	4	$67
Amarin Pharma, Inc.	4	$61
Novartis	3	$54
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	4	$54
Boston Scientific	3	$52
Pfizer	2	$35
Arbor Pharmaceuticals, Inc.	2	$31
E.r. Squibb & Sons, L.L.C.	2	$30
Gilead	1	$19
Irhythm Technologies, Inc.	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Reveal LINQ$1,521
Resolute$1,430

How this compares

$5,100 in reported general payments places this provider in the 30th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas →

Other interventional cardiology in Houston

Juan GranadaHouston$4.1M
John IsaacHouston$1.8M
Sanjay KunapuliHouston$267K
Michele SartoriHouston$266K
Abhijeet DhobleHouston$161K
Amir KashaniHouston$148K
Dhaval ParekhHouston$137K
Neal KleimanHouston$118K
Mehran MassumiHouston$114K
Eduardo HernandezHouston$112K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →